Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Valeo Pharma Inc (VPHIF)
:VPHIF
Holding VPHIF?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Sep 25, 2019
|% Change Since: 0.00%
|Next Earnings Date:Jul 03, 2019
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there were strong performances in the Respiratory and Specialty units, and cost-saving measures are progressing, the significant loss of revenue from the termination of Xiidra and increased net loss create challenges. The company is taking steps to improve financial flexibility and profitability, yet the overall situation remains challenging.Company Guidance
During the Valeo Pharma Q3 2024 earnings call, CEO Ali Moghaddam outlined several key metrics and financial adjustments. The company reported a total revenue of $12.6 million, marking an 11% decrease from Q3 2023's $14.1 million, primarily due to the termination of Xiidra, which accounted for a $2.5 million shortfall compared to the previous year and $2.8 million compared to Q2 2024. Excluding Xiidra, there was a 9% growth in continued business compared to Q3 2023. The Respiratory unit saw a 29% increase in revenue compared to Q2 2024, driven by Enerzair and Atectura prescriptions, which grew 74% year-over-year. The Specialty unit, led by Redesca, achieved a 21% growth over Q2 2024. The company also reported year-to-date revenues of $40.3 million, closely aligning with the $40.8 million from the previous year. Operational efficiency improvements were highlighted, with a focus on reducing OpEx, leading to a reported adjusted EBITDA loss of $1.5 million, a 40% improvement from the previous year's $2.5 million loss. The company aims to achieve EBITDA positive status by Q1 2025.Respiratory Unit Growth
The Respiratory unit demonstrated a revenue growth of 29% in Q3 2024 compared to Q2 2024. Enerzair and Atectura prescriptions increased by 74% year-over-year, with 4,285 physicians prescribing these medications.
Specialty Unit and Redesca Performance
The Specialty unit returned to growth with Redesca leading with a 21% growth in Q3 2024 compared to Q2 2024. Redesca's revenue grew by 18% year-over-year, and it is poised to benefit from favorable market trends.
Cost-Saving Initiatives
Cost-saving initiatives announced in November 2023 have started materializing, with expectations for continued improvement in operational efficiencies and profitability. The company is targeting EBITDA positive status by Q1 2025.
Amendment of Loan Agreement
An agreement with Sagard Healthcare Royalty Partners was amended, providing financial flexibility by extending the first CAD 10 million repayment deadline and reducing the principal owed by Valeo.
---
VPHIF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VPHIF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Sep 12, 2024 | $0.05 | $0.05 | 0.00% |
| Jun 13, 2024 | $0.12 | $0.10 | -16.67% |
| Mar 14, 2024 | $0.12 | $0.12 | 0.00% |
| Jan 29, 2024 | $0.25 | $0.21 | -16.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Valeo Pharma Inc (VPHIF) report earnings?
Valeo Pharma Inc (VPHIF) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Valeo Pharma Inc (VPHIF) earnings time?
Valeo Pharma Inc (VPHIF) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VPHIF EPS forecast?
Currently, no data Available
---